Literature DB >> 33804492

A Putative Amidase Endolysin Encoded by Clostridium perfringens St13 Exhibits Specific Lytic Activity and Synergizes with the Muramidase Endolysin Psm.

Hiroshi Sekiya1, Maho Okada2, Eiji Tamai1, Toshi Shimamoto3, Tadashi Shimamoto3, Hirofumi Nariya4.   

Abstract

Clostridium perfringens is an often-harmful intestinal bacterium that causes various diseases ranging from food poisoning to life-threatening fulminant disease. Potential treatments include phage-derived endolysins, a promising family of alternative antimicrobial agents. We surveyed the genome of the C. perfringens st13 strain and identified an endolysin gene, psa, in the phage remnant region. Psa has an N-terminal catalytic domain that is homologous to the amidase_2 domain, and a C-terminal domain of unknown function. psa and gene derivatives encoding various Psa subdomains were cloned and expressed in Escherichia coli as N-terminal histidine-tagged proteins. Purified His-tagged full-length Psa protein (Psa-his) showed C. perfringens-specific lytic activity in turbidity reduction assays. In addition, we demonstrated that the uncharacterized C-terminal domain has cell wall-binding activity. Furthermore, cell wall-binding measurements showed that Psa binding was highly specific to C. perfringens. These results indicated that Psa is an amidase endolysin that specifically lyses C. perfringens; the enzyme's specificity is highly dependent on the binding of the C-terminal domain. Moreover, Psa was shown to have a synergistic effect with another C. perfringens-specific endolysin, Psm, which is a muramidase that cleaves peptidoglycan at a site distinct from that targeted by Psa. The combination of Psa and Psm may be effective in the treatment and prevention of C. perfringens infections.

Entities:  

Keywords:  Clostridium perfringens; amidase; bacterial cell wall; endolysin; peptidoglycan

Year:  2021        PMID: 33804492      PMCID: PMC7999503          DOI: 10.3390/antibiotics10030245

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  47 in total

1.  Development and application of a method for counterselectable in-frame deletion in Clostridium perfringens.

Authors:  Hirofumi Nariya; Shigeru Miyata; Motoo Suzuki; Eiji Tamai; Akinobu Okabe
Journal:  Appl Environ Microbiol       Date:  2010-12-23       Impact factor: 4.792

Review 2.  Peptidoglycan recognition proteins: pleiotropic sensors and effectors of antimicrobial defences.

Authors:  Julien Royet; Roman Dziarski
Journal:  Nat Rev Microbiol       Date:  2007-04       Impact factor: 60.633

3.  Substrate-induced inactivation of the Escherichia coli AmiD N-acetylmuramoyl-L-alanine amidase highlights a new strategy to inhibit this class of enzyme.

Authors:  Anne Pennartz; Catherine Généreux; Claudine Parquet; Dominique Mengin-Lecreulx; Bernard Joris
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

Review 4.  Production and application of bacteriophage and bacteriophage-encoded lysins.

Authors:  Noémie M Dorval Courchesne; Albert Parisien; Christopher Q Lan
Journal:  Recent Pat Biotechnol       Date:  2009

Review 5.  Catalytic diversity and cell wall binding repeats in the phage-encoded endolysins.

Authors:  Sebastian S Broendum; Ashley M Buckle; Sheena McGowan
Journal:  Mol Microbiol       Date:  2018-11-13       Impact factor: 3.501

Review 6.  Peptidoglycan types of bacterial cell walls and their taxonomic implications.

Authors:  K H Schleifer; O Kandler
Journal:  Bacteriol Rev       Date:  1972-12

Review 7.  Novel insights into the epidemiology of Clostridium perfringens type A food poisoning.

Authors:  Miia Lindström; Annamari Heikinheimo; Päivi Lahti; Hannu Korkeala
Journal:  Food Microbiol       Date:  2010-04-13       Impact factor: 5.516

8.  Lytic activity of the staphylolytic Twort phage endolysin CHAP domain is enhanced by the SH3b cell wall binding domain.

Authors:  Stephen C Becker; Steven Swift; Olga Korobova; Nina Schischkova; Pavel Kopylov; David M Donovan; Igor Abaev
Journal:  FEMS Microbiol Lett       Date:  2014-12-04       Impact factor: 2.742

9.  Clostridium perfringens phospholipase C-induced platelet/leukocyte interactions impede neutrophil diapedesis.

Authors:  A E Bryant; C R Bayer; M J Aldape; R J Wallace; R W Titball; D L Stevens
Journal:  J Med Microbiol       Date:  2006-05       Impact factor: 2.472

10.  Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia.

Authors:  Jan M Doehn; Katja Fischer; Katrin Reppe; Birgitt Gutbier; Thomas Tschernig; Andreas C Hocke; Vincent A Fischetti; Jutta Löffler; Norbert Suttorp; Stefan Hippenstiel; Martin Witzenrath
Journal:  J Antimicrob Chemother       Date:  2013-04-30       Impact factor: 5.790

View more
  4 in total

Review 1.  Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens.

Authors:  Jennifer Venhorst; Jos M B M van der Vossen; Valeria Agamennone
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

2.  The Broad Host Range Phage vB_CpeS_BG3P Is Able to Inhibit Clostridium perfringens Growth.

Authors:  Sisi Huang; Yuan Tian; Yongjuan Wang; Pilar García; Banhong Liu; Rui Lu; Liting Wu; Hongduo Bao; Maoda Pang; Yan Zhou; Ran Wang; Hui Zhang
Journal:  Viruses       Date:  2022-03-25       Impact factor: 5.818

Review 3.  Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance.

Authors:  Raymond Schuch; Cara Cassino; Xavier Vila-Farres
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

4.  Biochemical Characterizations of the Putative Endolysin Ecd09610 Catalytic Domain from Clostridioides difficile.

Authors:  Hiroshi Sekiya; Hina Yamaji; Ayumi Yoshida; Risa Matsunami; Shigehiro Kamitori; Eiji Tamai
Journal:  Antibiotics (Basel)       Date:  2022-08-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.